ECSP055571A - Monoetanosulfonato de 3-z-[1-(4-(n-((4-metil-piperazina-1-il)-metilcarbonil)-n-metil-amino)-anilino)-1-fenil-metilen]-6-metoxicarbonil-2-indolinona y su utilización como medicamento - Google Patents

Monoetanosulfonato de 3-z-[1-(4-(n-((4-metil-piperazina-1-il)-metilcarbonil)-n-metil-amino)-anilino)-1-fenil-metilen]-6-metoxicarbonil-2-indolinona y su utilización como medicamento

Info

Publication number
ECSP055571A
ECSP055571A EC2005005571A ECSP055571A ECSP055571A EC SP055571 A ECSP055571 A EC SP055571A EC 2005005571 A EC2005005571 A EC 2005005571A EC SP055571 A ECSP055571 A EC SP055571A EC SP055571 A ECSP055571 A EC SP055571A
Authority
EC
Ecuador
Prior art keywords
methyl
indolinone
anilino
methylene
amino
Prior art date
Application number
EC2005005571A
Other languages
English (en)
Inventor
Werner Rall
Gerald Juergen Roth
Peter Sieger
Guenter Linz
Frank Hilberg
Thomas Bock
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=30469050&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP055571(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of ECSP055571A publication Critical patent/ECSP055571A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Objeto del presente invento es el compuesto monoetanosulfonato de 3-Z-[1-(4-(N-((4-metil-piperazina-1-il)-metilcarbonil)-N-metil-amino)-anilino)-1-fenil-metilen]-6-metoxicarbonil-2-indolinona de la fórmula I y su utilización como medicamento.
EC2005005571A 2002-07-24 2005-01-24 Monoetanosulfonato de 3-z-[1-(4-(n-((4-metil-piperazina-1-il)-metilcarbonil)-n-metil-amino)-anilino)-1-fenil-metilen]-6-metoxicarbonil-2-indolinona y su utilización como medicamento ECSP055571A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10233500A DE10233500A1 (de) 2002-07-24 2002-07-24 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-Monoethansulfonat und dessen Verwendung als Arzneimittel

Publications (1)

Publication Number Publication Date
ECSP055571A true ECSP055571A (es) 2005-04-18

Family

ID=30469050

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2005005571A ECSP055571A (es) 2002-07-24 2005-01-24 Monoetanosulfonato de 3-z-[1-(4-(n-((4-metil-piperazina-1-il)-metilcarbonil)-n-metil-amino)-anilino)-1-fenil-metilen]-6-metoxicarbonil-2-indolinona y su utilización como medicamento

Country Status (35)

Country Link
US (2) US7119093B2 (es)
EP (2) EP2386543A1 (es)
JP (1) JP5039279B2 (es)
KR (1) KR101145691B1 (es)
CN (1) CN100351235C (es)
AR (2) AR040662A1 (es)
AT (1) ATE551322T1 (es)
AU (1) AU2003254376B2 (es)
BR (1) BRPI0312811B8 (es)
CA (1) CA2493310C (es)
CY (1) CY1112916T1 (es)
DE (1) DE10233500A1 (es)
DK (1) DK1527047T3 (es)
EA (1) EA008684B1 (es)
EC (1) ECSP055571A (es)
EG (1) EG24562A (es)
ES (1) ES2384968T3 (es)
HR (1) HRP20050070B1 (es)
IL (2) IL166405A0 (es)
ME (1) ME00353B (es)
MX (1) MXPA04012785A (es)
MY (1) MY136883A (es)
NO (1) NO330486B1 (es)
NZ (1) NZ538367A (es)
PE (1) PE20040704A1 (es)
PL (1) PL223758B1 (es)
PT (1) PT1527047E (es)
RS (1) RS52283B (es)
SA (1) SA03240446B1 (es)
SI (1) SI1527047T1 (es)
TW (1) TWI285635B (es)
UA (1) UA78352C2 (es)
UY (1) UY27904A1 (es)
WO (1) WO2004013099A1 (es)
ZA (1) ZA200409814B (es)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10233500A1 (de) * 2002-07-24 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-Monoethansulfonat und dessen Verwendung als Arzneimittel
US20040204458A1 (en) * 2002-08-16 2004-10-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of Lck inhibitors for treatment of immunologic diseases
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
PE20060777A1 (es) * 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
WO2007057397A1 (en) * 2005-11-15 2007-05-24 Boehringer Ingelheim International Gmbh Treatment of cancer
EP1870400A1 (en) * 2006-06-08 2007-12-26 Boehringer Ingelheim Pharma GmbH & Co. KG Salts and crystalline salt forms of an 2-indolinone derivative
ES2435454T3 (es) 2007-06-21 2013-12-19 Janssen Pharmaceutica, N.V. Indolin-2-onas y aza-indolin-2-onas
EP2229359B1 (en) * 2007-12-03 2017-11-29 Boehringer Ingelheim International GmbH Process for the manufacture of an indolinone derivative
PE20091445A1 (es) * 2007-12-03 2009-10-19 Boehringer Ingelheim Int Derivados de indolinona y procedimiento para su fabricacion
US20170065529A1 (en) 2015-09-09 2017-03-09 Boehringer Ingelheim International Gmbh Pharmaceutical dosage form for immediate release of an indolinone derivative
UA107560C2 (uk) * 2008-06-06 2015-01-26 Фармацевтична лікарська форма для негайного вивільнення похідної індолінону
JP5993573B2 (ja) 2008-06-06 2016-09-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 医薬組み合わせ
LT2299987T (lt) * 2008-06-06 2018-05-25 Boehringer Ingelheim International Gmbh Farmacinės vaisto formos kapsulė, apimanti indolinono darinio suspensijos kompoziciją
EP2387401A1 (en) 2009-01-14 2011-11-23 Boehringer Ingelheim International GmbH Method for treating colorectal cancer
US8802384B2 (en) 2009-03-12 2014-08-12 Boehringer Ingelheim International Gmbh Method or system using biomarkers for the monitoring of a treatment
EP2429527A1 (en) * 2009-05-14 2012-03-21 Boehringer Ingelheim International GmbH New combination therapy in treatment of cancer and fibrotic diseases
WO2010130757A1 (en) 2009-05-14 2010-11-18 Boehringer Ingelheim International Gmbh New combination therapy in treatment of oncological and fibrotic diseases
US20120107304A1 (en) 2010-04-27 2012-05-03 Boehringer Ingelheim International Gmbh Combination therapy in treatment of oncological and fibrotic diseases
WO2012068441A2 (en) 2010-11-19 2012-05-24 Ratiopharm Gmbh Intedanib salts and solid state forms thereof
WO2013059740A1 (en) 2011-10-21 2013-04-25 Foundation Medicine, Inc. Novel alk and ntrk1 fusion molecules and uses thereof
JP2015524400A (ja) 2012-07-19 2015-08-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ９−［４−（３−クロロ−２−フルオロ−フェニルアミノ）−７−メトキシ−キナゾリン−６−イルオキシ］−１，４−ジアザ−スピロ［５．５］ウンデカン−５−オンのフマル酸塩、その薬物としての使用及び調製
ES2949394T3 (es) 2012-11-05 2023-09-28 Found Medicine Inc Moléculas de fusión novedosas y usos de las mismas
WO2014071358A2 (en) 2012-11-05 2014-05-08 Foundation Medicine, Inc. Novel ntrk1 fusion molecules and uses thereof
CA3150658A1 (en) 2013-01-18 2014-07-24 Foundation Medicine, Inc. Methods of treating cholangiocarcinoma
US20140350022A1 (en) 2013-05-10 2014-11-27 Boehringer Ingelheim International Gmbh Efficacious treatment of NSCLC and predictive clinical marker of the responsiveness of a tumour to a treatment
CN104003925B (zh) * 2013-06-05 2016-03-30 四川大学 吲哚酮化合物或其衍生物及其用途
WO2015009889A1 (en) * 2013-07-18 2015-01-22 Concert Pharmaceuticals, Inc. Deuterated intedanib derivatives and their use for the treatment of proliferative disorders
CA3172586C (en) 2013-07-31 2025-10-14 Avalyn Pharma Inc. IMATINIB AEROSOL COMPOUNDS AND RELATED USES
US20170114323A1 (en) * 2014-06-19 2017-04-27 Whitehead Institute For Biomedical Research Uses of kinase inhibitors for inducing and maintaining pluripotency
CN106008308A (zh) * 2015-03-13 2016-10-12 正大天晴药业集团股份有限公司 尼达尼布乙磺酸盐结晶
WO2016178064A1 (en) 2015-05-06 2016-11-10 Suven Life Sciences Limited Polymorph of nintedanib ethanesulphonate, processes and intermediates thereof
CN105126909B (zh) * 2015-07-13 2018-01-23 淮海工学院 固载钯催化剂在4‑苯乙炔基‑3‑硝基苯甲酸甲酯合成中的应用
CN105001143A (zh) * 2015-07-24 2015-10-28 南京正大天晴制药有限公司 一种制备高纯度乙磺酸尼达尼布的方法
CN106432042A (zh) * 2015-08-13 2017-02-22 南京华威医药科技开发有限公司 尼达尼布乙磺酸水合物的药物新晶型
WO2017077551A2 (en) * 2015-11-03 2017-05-11 Mylan Laboratories Limited An amorphous nintedanib esylate and solid dispersion thereof
CZ2016104A3 (cs) * 2016-02-24 2017-09-06 Zentiva, K.S. Krystalické modifikace solí methyl (3Z)-3-{[(4-{methyl[(4-methylpiperazin-1-yl)acetyl]amino}fenyl)amino](fenyl)methyliden}-2-oxo-2,3-dihydro-1H-indol-6-karboxylátu a způsoby jejich přípravy
WO2017178428A1 (en) 2016-04-13 2017-10-19 Boehringer Ingelheim International Gmbh Pharmaceutical combination of nintedanib, trifluridine and tipiracil for treating colorectal cancer
EP3246029A1 (en) 2016-05-19 2017-11-22 Boehringer Ingelheim International Gmbh Pharmaceutical combination of nintedanib and capecitabine for the treatment of colorectal cancer
CN109415314A (zh) * 2016-05-19 2019-03-01 上海诚妙医药科技有限公司 尼达尼布的新晶型及其制备方法及其用途
EP3464240A1 (en) 2016-05-27 2019-04-10 Boehringer Ingelheim International GmbH Use of ecm biomarkers for the determining the treatment onset with nintedanib and pirfenidone
WO2017207643A1 (en) 2016-06-01 2017-12-07 Boehringer Ingelheim International Gmbh Use of ecm biomarkers for the determining the treatment onset with nintedanib and pirfenidone
ITUA20164213A1 (it) * 2016-06-08 2017-12-08 Olon Spa Polimorfo di nintedanib
JP7018939B2 (ja) 2016-09-26 2022-02-14 ルヤン （スーチョウ） バイオロジー サイエンス アンド テクノロジー カンパニー，リミテッド 眼疾患の治療のための組成物ならびに使用および調製方法
US20200069679A1 (en) 2016-12-12 2020-03-05 Boehringer Ingelheim International Gmbh Nintedanib for use in methods for the treatment of interstitial lung diseases by coadministration with oladaterol
US10981896B2 (en) * 2017-03-02 2021-04-20 Board Of Regents, The University Of Texas System Indolinone derivatives as inhibitors of maternal embryonic leucine zipper kinase
WO2018165865A1 (zh) * 2017-03-14 2018-09-20 新源生物科技股份有限公司 3-z-[1-(4-(n-((4-甲基-哌嗪-1-基)-甲羰基)-n-甲基-氨基)-苯氨基)-1-苯基-亚甲基]-6-甲氧羰基-2-吲哚满酮的晶型
TWI632133B (zh) * 2017-03-15 2018-08-11 新源生物科技股份有限公司 ３－ｚ－［１－（４－（ｎ－（（４－甲基－哌嗪－１－基）－甲羰基）－ｎ－甲基－胺基）－苯胺基）－１－苯基－亞甲基］－６－甲氧羰基－２－吲哚啉酮的晶型
TWI676617B (zh) * 2017-03-15 2019-11-11 新源生物科技股份有限公司 3-z-[1-(4-(n-((4-甲基-呱嗪-1-基)-甲羰基)-n-甲基-胺基)-苯胺基)-1-苯基-亞甲基]-6-甲氧羰基-2-吲哚啉酮的晶型
WO2018177893A1 (en) 2017-03-28 2018-10-04 Boehringer Ingelheim International Gmbh Nintedanib for use in methods for the treatment of muscular dystrophy
WO2019048974A1 (en) * 2017-09-06 2019-03-14 Glenmark Pharmaceuticals Limited Process for the preparation of nintedanib
HUE072914T2 (hu) 2017-10-23 2025-12-28 Boehringer Ingelheim Int Új hatóanyag-kombináció progresszív fibrotizáló intersticiális tüdõbetegségek(PF-ILd) kezelésére
WO2019097112A1 (en) 2017-11-17 2019-05-23 Fermion Oy Synthesis of a 2-indolinone derivative known as intermediate for preparing nintedanib
PT3761980T (pt) 2018-03-07 2024-02-29 Pliant Therapeutics Inc Compostos de aminoácidos e métodos de utilização
TWI770624B (zh) 2018-06-15 2022-07-11 漢達生技醫藥股份有限公司 尼洛替尼十二烷基硫酸鹽在製備用於治療慢性骨髓性白血病之劑型的用途
KR102906597B1 (ko) 2018-08-22 2026-01-02 아발린 파마 아이엔씨. 흡입형 닌테다닙 및 닌테다닙 염의 특수 제형 조성물
CN109988094B (zh) * 2019-04-29 2020-04-14 石药集团中奇制药技术（石家庄）有限公司 一种乙磺酸尼达尼布的制备方法
IL293474A (en) 2019-12-04 2022-08-01 Idorsia Pharmaceuticals Ltd Combination of lpa1 receptor antagonist aztidine with pirfenidone and/or nintedanib for use in the treatment of fibrotic diseases
JP2023519600A (ja) 2020-04-01 2023-05-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 線維性状態の治療におけるバイオマーカーの使用
EP4149475A1 (en) 2020-05-22 2023-03-22 QX Therapeutics Inc. Compositions and methods for treating lung injuries associated with viral infections
AU2021321561A1 (en) * 2020-08-07 2023-03-09 Bdr Lifesciences Private Limited An improved highly efficient process for the prepration of nintedanib and pharmaceutically acceptable salt thereof
CN111848490B (zh) * 2020-08-24 2021-09-24 江西国药有限责任公司 一种高纯度乙磺酸尼达尼布的制备方法
CN113024439A (zh) * 2021-03-28 2021-06-25 郑州大学 尼达尼布乙磺酸盐新晶型ⅰ的制备
EP4098246A1 (en) 2021-05-31 2022-12-07 Lotus Pharmaceutical Co., Ltd. Formulation of nintedanib
US20250161250A1 (en) 2022-02-28 2025-05-22 Nuformix Technologies Limited Compositions and methods for treatment of idiopathic pulmonary fibrosis
JP2025525881A (ja) 2022-08-16 2025-08-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 眼内使用するためのニンテダニブの医薬製剤
KR20240042322A (ko) 2022-09-23 2024-04-02 삼아제약 주식회사 티로신 키나제 저해제를 유효성분으로 하는 약제학적 조성물
EP4578443A1 (en) 2023-12-27 2025-07-02 Faran S.A. Oral suspensions comprising nintedanib esylate
KR20250118711A (ko) 2024-01-30 2025-08-06 삼아제약 주식회사 티로신 키나제 저해제를 유효성분으로 하는 생체이용률이 개선된 경구투여용 제제
WO2025261988A1 (fr) 2024-06-17 2025-12-26 Assistance Publique Hopitaux De Paris Utilisation de nintédanib pour le traitement de la maladie de castleman

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB395546A (en) 1931-10-12 1933-07-20 Robert Pauli Scherer Method of and apparatus for making capsules
US2720463A (en) 1950-11-17 1955-10-11 American Cyanamid Co Gelatin capsule casting composition preparation
US2870062A (en) 1956-04-27 1959-01-20 Scherer Corp R P Gelatin composition for capsules
EP0169398B1 (de) 1984-07-24 1990-08-29 R.P. Scherer GmbH Oxytetracyclin-HC1-Weichgelatinekapseln und Verfahren zu ihrer Herstellung
GB9718913D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
DE19816624A1 (de) * 1998-04-15 1999-10-21 Boehringer Ingelheim Pharma Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
AU772189B2 (en) * 1999-08-23 2004-04-08 Solvay Pharmaceuticals B.V. New phenylpiperazines
UA75054C2 (uk) * 1999-10-13 2006-03-15 Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг Заміщені в положенні 6 індолінони, їх одержання та їх застосування як лікарського засобу
DE19949209A1 (de) * 1999-10-13 2001-04-19 Boehringer Ingelheim Pharma In 5-Stellung substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
US6762180B1 (en) * 1999-10-13 2004-07-13 Boehringer Ingelheim Pharma Kg Substituted indolines which inhibit receptor tyrosine kinases
DE10117204A1 (de) * 2001-04-06 2002-10-10 Boehringer Ingelheim Pharma In 6-Stellung substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
DE10233500A1 (de) * 2002-07-24 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-Monoethansulfonat und dessen Verwendung als Arzneimittel

Also Published As

Publication number Publication date
AR040662A1 (es) 2005-04-13
EP2386543A1 (en) 2011-11-16
CN1671660A (zh) 2005-09-21
NO20050985L (no) 2005-02-23
ES2384968T3 (es) 2012-07-16
US7119093B2 (en) 2006-10-10
IL166405A (en) 2009-11-18
US20040176392A1 (en) 2004-09-09
EA008684B1 (ru) 2007-06-29
UA78352C2 (uk) 2007-03-15
MY136883A (en) 2008-11-28
MEP53708A (en) 2011-05-10
SA03240446B1 (ar) 2007-07-31
PL372996A1 (en) 2005-08-08
NO330486B1 (no) 2011-04-26
CA2493310A1 (en) 2004-02-12
ME00353B (me) 2011-10-10
HRP20050070A2 (en) 2005-12-31
HK1078851A1 (zh) 2006-03-24
EP1527047B1 (en) 2012-03-28
EG24562A (en) 2009-10-25
WO2004013099A1 (en) 2004-02-12
PT1527047E (pt) 2012-06-28
ZA200409814B (en) 2006-02-22
UY27904A1 (es) 2004-02-27
AU2003254376A1 (en) 2004-02-23
IL166405A0 (en) 2006-01-15
JP2005535684A (ja) 2005-11-24
KR20050042139A (ko) 2005-05-04
BRPI0312811B8 (pt) 2021-05-25
CN100351235C (zh) 2007-11-28
CY1112916T1 (el) 2016-04-13
TW200409754A (en) 2004-06-16
EP1527047A1 (en) 2005-05-04
MXPA04012785A (es) 2005-06-08
RS52283B (sr) 2012-10-31
CA2493310C (en) 2011-01-18
BR0312811A (pt) 2005-04-19
AU2003254376B2 (en) 2010-06-17
EA200500146A1 (ru) 2005-08-25
NZ538367A (en) 2008-01-31
KR101145691B1 (ko) 2012-05-25
BRPI0312811A8 (pt) 2019-01-02
RS20050046A (sr) 2007-09-21
SI1527047T1 (sl) 2012-07-31
BRPI0312811B1 (pt) 2019-03-12
PL223758B1 (pl) 2016-10-31
DK1527047T3 (da) 2012-07-16
US20060258681A1 (en) 2006-11-16
HRP20050070B1 (hr) 2013-09-30
PE20040704A1 (es) 2004-11-29
DE10233500A1 (de) 2004-02-19
TWI285635B (en) 2007-08-21
JP5039279B2 (ja) 2012-10-03
ATE551322T1 (de) 2012-04-15
AR094217A2 (es) 2015-07-15

Similar Documents

Publication Publication Date Title
ECSP055571A (es) Monoetanosulfonato de 3-z-[1-(4-(n-((4-metil-piperazina-1-il)-metilcarbonil)-n-metil-amino)-anilino)-1-fenil-metilen]-6-metoxicarbonil-2-indolinona y su utilización como medicamento
ECSP066399A (es) Metanosulfonato del éster etílico del ácido 3-[(2-{[4-(hexiloxicarbonilamino-imino-metil)-fenilamino]-metil}-1-metil-1h-bencimidazol-5-carbonil)-piridin-2-il-amino]-propiónico y su utilización como medicamento
ECSP045474A (es) 1-(aminoalquil)-3-sulfonilazaindoles como ligandos de 5-hidroxitriptamina-6
CR20120051A (es) Derivados de piridina y pirazina como moduladores de cinasa de proteína
ECSP066365A (es) Anilino purinas sustituidas en la posición 6 útiles como inhibidores de rtk
UY30316A1 (es) Derivados sustituidos de benzamidas, nicotinamidas, propanamidas, acetamidas y carboxamidas n-(2-(piperidin-1-ilmetil)ciclohexil)sustituidas, procesos de preparacion, composiciones conteniéndolos y aplicaciones
ATE493386T1 (de) Trans-3-aza-bicyclo-ä3.1.0ü-hexan-derivate
CY1111733T1 (el) Παραγωγα 2-(1η-ινδολυλοσουλφανυλ)-βενζυλαμινης ως ssri
NZ612000A (en) Bicyclo[3.2.1]octyl amide derivatives and uses of same
IN2012DN01378A (es)
MX338001B (es) Forma de dosificacion farmaceutica para la liberacion inmediata de un derivado de indolinona.
CY1111454T1 (el) Παραγωγα φαινυλο-πυραζολιου ως συνδετες υποδοχεα μη στεροειδων γλυκοκορτικοειδων
CY1120433T1 (el) Θεραπεια αγωνιστων μελατονινης
CY1112646T1 (el) Θεραπευτικες χρησεις ενωσεων που εχουν συνδυασμενη δραστικοτητα sert, 5-ητ3 και 5-ητ1α
UY28923A1 (es) Compuestos terapéuticos: piridina como estructura base
UY30289A1 (es) Derivados de la 1h-pirrol-3-carboxamida sustituida con 1-(tetrahidro-2h-piran-4-il-metil)-1h-bencimidazol, composiciones conteniéndolos, procedimientos de preparacion y aplicaciones
MA32639B1 (fr) [4-(5-aminométhyl-2-fluoro-phényl)-pipéridin- 1-yl]-[7-fluoro-1- (2-méthoxy-éthyl)-4-trifluorométhoxy-1h-indol-3-yl]-méthanone en tant qu'inhibiteur de la tryptase de mastocytes
CY1114400T1 (el) Θεραπευτικες εφαρμογες των παραγωγων κιναζολινεδιονης
CL2008001820A1 (es) Compuestos derivados de aril-isoxasol-imidazol; procedimiento de preparacion; composicion farmaceutica que los contiene; y uso en la preparacion de medicamentos utiles en el tratamiento de trastornos cognitivos y enfermedades relacionadas con alzheimer.
AR077139A1 (es) Composiciones farmaceuticas utiles para tratar el vch
CY1112718T1 (el) Ν- (2-υδροξυαιθυλ) -ν-μεθυλ-4- (κινολιν-8-υλ (1- (θειαζολ-4-υλμεθυλ) πιπεριδιν- 4 -υλιδενο) μεθυλ) βενζαμιδιο, η μεθοδος παρασκευης του καθως και η χρηση του για τη θεραπευτικη αγωγη πονου, αγχους και καταθλιψης
ATE501121T1 (de) 4-ä(3- fluorphenoxy)phenylmethylüpiperidinmethandsulfo atverwendungen, syntheseverfahren und pharmazeutische zusammensetzungen
MX2009005544A (es) Indoles.
CR9436A (es) Derivados de aril 1,4-pirazina sustituidos
GEP20115322B (en) Non-peptide bradykinin antagonists and pharmaceutical compositions therefrom